SAB Biotherapeutics (SABS) News Today → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Free SABS Stock Alerts $4.00 -0.10 (-2.44%) (As of 03:59 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSAB Biotherapeutics (NASDAQ:SABS) Shares Up 3.8%americanbankingnews.com - May 8 at 3:50 AMSAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directorsglobenewswire.com - May 6 at 7:15 AMSAB Biotherapeutics (SABS) Price Target Decreased by 10.00% to 18.36msn.com - April 17 at 12:05 PMSAB Leaps on Completing Latest Cohortmsn.com - April 16 at 11:03 AMSAB Biotherapeutics Provides SAB-142 Trial Updateglobenewswire.com - April 16 at 7:15 AMSAB Biotherapeutics to Present at INNODIA Annual Meetingglobenewswire.com - April 8 at 7:15 AMSAB Biotherapeutics: Strong Financial Position and Promising SAB-142 Pipeline Merit Buy Ratingmarkets.businessinsider.com - April 4 at 7:44 AMSAB Biotherapeutics to Present at the Needham Virtual Healthcare Conferenceglobenewswire.com - April 4 at 7:15 AMSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - April 1 at 11:25 AMSAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - April 1 at 11:25 AMSAB Biotherapeutics Reports Full Year 2023 Operating and Financial Resultsglobenewswire.com - March 29 at 7:15 AMSAB Collaborates With Naval Medical Research To Develop Potential Influenza Treatment; Stock Dropsmarkets.businessinsider.com - March 25 at 3:41 PMSAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatmentglobenewswire.com - March 25 at 10:15 AMSAB Biotherapeutics to Present at the BIO CEO & Investor Conferenceglobenewswire.com - February 23 at 8:00 AMSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 8 at 12:42 PMSAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 8 at 12:42 PMSAB Biotherapeutics Names Samuel Reich Chief Executivemarketwatch.com - February 2 at 10:20 AMSAB Biotherapeutics' Executive Chairman Reich Takes On Addl. Role As CEOmarkets.businessinsider.com - February 2 at 10:20 AMSAB Biotherapeutics Announces Executive Leadership Changefinance.yahoo.com - February 2 at 10:20 AMmarketbeat.com - January 29 at 9:58 AMSAB Biotherapeutics, Inc.: SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirementfinanznachrichten.de - January 24 at 6:44 AMSAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirementfinance.yahoo.com - January 23 at 8:13 PMAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)markets.businessinsider.com - January 8 at 10:57 PMIndividual investors are SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners and were rewarded after market cap rose by US$535m last weekfinance.yahoo.com - January 5 at 9:00 AMmarketbeat.com - January 5 at 6:04 AMSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces 1-for-10 Reverse Stock Splitfinanznachrichten.de - January 3 at 7:24 PMSAB Biotherapeutics Announces 1-for-10 Reverse Stock Splitfinance.yahoo.com - January 2 at 7:10 PMHere's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock Nowfinance.yahoo.com - December 8 at 3:18 PMVerifyMe And 3 Other Stocks Under $2 Insiders Are Buyingmsn.com - December 1 at 3:14 PMSAB Biotherapeutics Starts Human Clinical Trial of Diabetes Treatmentfinance.yahoo.com - November 29 at 2:52 PMEXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australiamsn.com - November 29 at 9:47 AMSAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetesfinance.yahoo.com - November 29 at 9:47 AMSAB Biotherapeutics, Inc.: SAB Biotherapeutics Appoints Katie Ellias to the Board of Directorsfinanznachrichten.de - November 20 at 1:54 PMSAB Biotherapeutics Appoints Katie Ellias to the Board of Directorsfinance.yahoo.com - November 20 at 8:54 AMSAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updatesfinanznachrichten.de - November 14 at 4:22 PMSAB Biotherapeutics GAAP EPS of -$0.10msn.com - November 14 at 4:22 PMSAB Biotherapeutics 3Q Loss Narrows, Completes $67.1M in Financingfinance.yahoo.com - November 14 at 4:22 PMSAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updatesfinance.yahoo.com - November 14 at 9:16 AMSAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetesfinance.yahoo.com - November 14 at 9:16 AMSAB Biotherapeutics to Present at Piper Sandler Healthcare Conferencefinance.yahoo.com - November 9 at 9:32 AMSAB Biotherapeutics files to sell 412.7M units to noteholdersmsn.com - November 6 at 1:53 PMSAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officerfinance.yahoo.com - October 24 at 8:11 AMAnalysts Are Bullish on Top Healthcare Stocks: SAB Biotherapeutics (SABS), Elevance Health (ELV)markets.businessinsider.com - October 19 at 12:17 PMSAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetesfinance.yahoo.com - October 19 at 12:17 PMSAB Biotherapeutics’ Financial Stability and Potential Growth: A Comprehensive Analysis of Edward White’s Buy Ratingmarkets.businessinsider.com - October 6 at 2:51 PMSecured Financing and Promising Clinical Developments Bolster Buy Rating for SAB Biotherapeuticsmarkets.businessinsider.com - October 6 at 9:51 AMSAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directorsfinance.yahoo.com - October 5 at 8:43 AMSAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directorsfinance.yahoo.com - October 5 at 8:43 AMSAB Biotherapeutics Will Sell $130 Million Shares of Preferred Stock to Advance Diabetes Treatmentfinance.yahoo.com - October 3 at 1:38 PMEXLUSIVE: SAB Biotherapeutics To Raise Up To $130M Via Preferred Equity To Advance Development Of Lead Diabetes Candidatefinance.yahoo.com - October 2 at 12:34 PM Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here SABS Media Mentions By Week SABS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SABS News Sentiment▼0.340.36▲Average Medical News Sentiment SABS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SABS Articles This Week▼21▲SABS Articles Average Week Get SAB Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CRIS News Today SGMO News Today DYAI News Today CYTH News Today OKYO News Today NKGN News Today SRZN News Today INKT News Today TARA News Today QNCX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SABS) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SAB Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
